NCT06685848 2026-01-07
Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion
Hemanext
Phase NA Recruiting
Clinical Trials
3 trialsNCT05119335 2025-11-12
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
NiKang Therapeutics, Inc.
Phase 1/2 Terminated
NCT05549232 2025-07-23
Hypoxic Red Blood Cells for Burns and Hematological Malignancies at Haukeland University Hospital
Hemanext
Completed